Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220204640COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
US 30.06.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No 17655136 Applicant Genentech, Inc. Inventor Mark Dennis

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

2.20220202809METHODS OF TREATING DEPRESSION WITH VORTIOXETINE
US 30.06.2022
Int.Class A61K 31/495
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
Appl.No 17220515 Applicant Rundle Research LLC Inventor Sundar SRINIVASAN

The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and/or different CYP2D6 metabolizer status.

3.20220202884COMPOSITIONS AND METHODS OF USING SENECA VALLEY VIRUS (SVV) FOR TREATING CANCER
US 30.06.2022
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No 17601768 Applicant SENECA THERAPEUTICS, INC. Inventor Paul L. HALLENBECK

Provided herein are compositions and methods of using Seneca Valley Virus (SW), or a derivative thereof, combined with an IFN-I inhibitor for treating a cancer in a subject. The disclosed methods particularly rely upon the expression level of an ANTXR1 and the expression level of IFN-I in the cancer from the subject. Also provided herein are methods for predicting the efficacy of an SW treatment and a kit for determining the same.

4.20220202785SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS
US 30.06.2022
Int.Class A61K 31/433
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
433Thiadiazoles
Appl.No 17602101 Applicant UNIVERSITY OF MARYLAND, BALTIMORE Inventor Charles C. HONG

The invention relates to a class of small molecule inhibitors of GPR68/OGR1, a proton-sensing/stretch-sensing/sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19.

5.WO/2022/138351TUMOR ANALYSIS SYSTEM
WO 30.06.2022
Int.Class C12M 1/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
34Measuring or testing with condition measuring or sensing means, e.g. colony counters
Appl.No PCT/JP2021/046157 Applicant HITACHI, LTD. Inventor ABE Sachiho
The present invention provides a system for analyzing the composition of cells in a tumor specimen. This system is characterized by including at least a calculation unit and is characterized in that at least one storage apparatus included in the system or connected to the system includes: the cell composition of a cancer clone obtained from cells included in the tumor specimen on the basis of gene mutation information; and the cell composition of normal cells obtained from cells included in the tumor specimen on the basis of a gene expression level, the system also being characterized in that the calculation unit executes: a step for adjusting the abundance ratios of each cell species, such that the total of the abundance ratios of each cell species is X (X is a constant of 0 to 1 inclusive and is a parameter designated by a user of the system) with respect to the cell composition of the cancer clone and the cell composition of the normal cells read out from the storage apparatus while taking it into consideration that normal cells are included in the unclassified cells out of the cell composition of the cancer clone; and a step for outputting the cell composition of the tumor specimen after the adjustment.
6.WO/2022/138696PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS INFECTIONS
WO 30.06.2022
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/JP2021/047492 Applicant UNIVERSITY OF TSUKUBA Inventor KAWAGUCHI, Atsushi
The present invention provides a novel drug for the prevention or treatment of coronavirus infections. The present invention relates to a pharmaceutical composition that contains a substance capable of forming a complex with an estrogen receptor and that is for preventing or treating coronavirus infections.
7.WO/2022/138936MYELIN SHEATH REPAIR AGENT
WO 30.06.2022
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/JP2021/048303 Applicant NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY Inventor IKEDA Rieko
The present invention provides an agent for the treatment or prevention of central demyelinating diseases that contains an APJ receptor agonist.
8.WO/2022/139341PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBSESSIVE-COMPULSIVE DISORDER, TIC DISORDER, OR TOURETTE SYNDROME COMPRISING CLEMASTINE
WO 30.06.2022
Int.Class A61K 31/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Appl.No PCT/KR2021/019253 Applicant STANDIGM INC. Inventor CHOO, Hyunah
The present invention relates to: a pharmaceutical composition for the prevention or treatment of obsessive-compulsive disorder, tic disorder, or tourette syndrome, the pharmaceutical composition comprising clemastine or a pharmaceutically acceptable salt thereof as an active ingredient; a food composition; a method for preventing or treating obsessive-compulsive disorder, tic disorder, or tourette syndrome by using same; and use thereof. The pharmaceutical composition according to the present invention has an excellent effect of reducing repetitive behavior patterns, and thus is useful for the prevention or treatment of repetitive behavior disorder such as obsessive-compulsive disorder, tic disorder, or tourette syndrome.
9.WO/2022/140181METHODS OF ADMINISTERING INTRAVENOUS BACLOFEN
WO 30.06.2022
Int.Class A61K 31/197
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
Appl.No PCT/US2021/064055 Applicant ALLAYSIS, LLC Inventor DIAZ, Gilberto
Methods tor the intravenous (IV) administration of a therapeutically effective amount of baclofen at a dosing regimen winch mimics the oral pharmacokinetic profile of baclofen are disclosed. The disclosed methods meet bioequivalence criteria for both systemic exposure (AUC) and maximum plasma concentration (Cmax) compared to oral administration.
10.WO/2022/140241COMPOSITIONS TARGETING TUMOR ASSOCIATED MACROPHAGES AND METHODS USING SAME
WO 30.06.2022
Int.Class A61K 38/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
Appl.No PCT/US2021/064316 Applicant RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY Inventor PASQUALINI, Renata
In one aspect, the present disclosure relates to tumor associated macrophage (TAM) targeting peptide. In another aspect, the present disclosure relates to a method of targeting a TAM in a subject, the method comprising administering to the subject a TAM targeting peptide attached to and/or displayed on the surface of a solid particle. In yet another aspect, the present disclosure relates to a method of treating a tumor infiltrated with a TAM in a subject, the method comprising administering to the subject a TAM targeting peptide attached to and/or displayed on the surface of a solid particle.